PDR MEMBER LOGIN:
  • PDR Search

    Required field
  • Advertisement
  • FDA Date: 05/21/2015

    Prolia (denosumab) Injection REMS

    Goal of the Prolia (denosumab) Injection REMS Program

    The goal of the PROLIA REMS is to mitigate the risks of hypocalcemia, osteonecrosis of the jaw, atypical femoral fractures, serious infections, and dermatologic reactions by:

    a. informing healthcare providers and patients about the risks of (1) hypocalcemia, (2) osteonecrosis of the jaw, (3) atypical femoral fractures, (4) serious infections, and (5) dermatologic reactions associated with PROLIA

    b. informing healthcare providers they should counsel patients about the risks associated with PROLIA.

    REMS Elements

    • Medication Guide

    • Communication Plan